ABVC BioPharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development of new drugs and medical devices. The firm's product pipeline includes ABV-1501, which is a combination therapy for triple negative breast cancer, ABV-1504, which is a botanical reuptake inhibitor that targets norepinephrine, ABV-1505 for treating attention deficit hyperactivity disorder, ABV-1702 to treat myelodysplastic syndromes, ABV-1703 for Pancreatic Cancer, ABV-1601 for treating depression in cancer patients, ABV-1701, which is a vitreous substitute for vitrectomy, ABV-2001, and ABV-2002. The company was founded in 1990 and is headquartered in Fremont, CA.

First Foundation, Inc. is a bank holding, which engages in the provision of a comprehensive platform of financial services to individuals, businesses, and organizations. It operates through the following segments: Banking, Wealth Management, and Other. The company was founded by John Avak Hakopian and Ulrich Emanuel Keller, Jr. in 1990 and is headquartered in Dallas, TX.

DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6, Dexcom G7, Dexcom Stelo, Dexcom Share, Dexcom Real-Time API, and Dexcom ONE. The company was founded by John F. Burd on May 13, 1999 and is headquartered in San Diego, CA.

Aon Plc engages in the provision of risk, health, and wealth solutions. It focuses on risk capital including claim management, reinsurance, risk analysis, management, retention, and transfer; and human capital involving analytics, health and benefits, investments, pensions and retirement, talent and rewards, and workplace wellbeing. The company was founded in 1982 and is headquartered in Dublin, Ireland.

Hub Cyber Security (Israel) Ltd. engages in the development of computer software and the establishment of quality and reliability systems. It operates through the following segments: Consulting, Software, Training, and Software Testing and Outsourcing. The Consulting segment provides engineering and management consulting services in the fields of management and establishment of quality and reliability systems, reliability and safety analyzes, improvement works of processes and products, risk analysis and management, writing procedures and analytical reports, certification of organizations and companies according to accepted standards. The Software segment engages in software development for calculating reliability and safety data, for collecting and reporting incidents and faults, as well as databases. The Training segment engages in trainings and certifications in the areas of quality, safety, reliability and as part of training for the IDF, in the fields of command, management, organizational behavior, and preparation for military service. The Software Testing and Outsourcing segment provides solutions and services in the fields of test engineering, formation and characterization of processes, establishment of test groups and laboratories, development of quality indices, implementation of test methodologies in accordance with the organization's strategy and placement of employees in the above fields. The company was founded by Zigmund Bluvband on June 13, 1984 and is headquartered in Tel Aviv, Israel.

VNET Group, Inc. is a holding company, which engages in the provision of carrier-neutral internet data center services. Its services include interconnectivity, colocation or data center managed hosting services, and cloud services. The company was founded by Sheng Chen and Jun Zhang on October 16, 1999 and is headquartered in Beijing, China.

Telomir Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical company. It focuses on the development and commercialization of TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic treatment for human stem cells. The firm's initial focus on treatments to inhibit the production of pro-inflammatory cytokines, such as IL-17, by oral administration of TELOMIR-1 as a therapeutic treatment for stem cells in situ. TELOMIR-1 is under investigation to provide a potential therapeutic intervention against age-related inflammatory conditions such as hemochromatosis, as well as for post-chemotherapy recovery, by interrupting and preventing the IL-17 induced inflammatory pathways that create the systemic imbalance of cellular metals. The company was founded on August 26, 2021 and is headquartered in Baltimore, MD.

Techprecision Corp. engages in the business of metal fabrication and precision machining. It focuses on the manufacture of precision, large-scale fabricated and machined metal components and systems. The company was founded by Andrew A. Levy in February 2005 and is headquartered in Westminster, MA.

Cabaletta Bio, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor to selectively bind and eliminate B cells that produce disease-causing autoantibodies. The company was founded by Michael C. Milone, Steven Nichtberger, and Aimee Payne in April 2017 and is headquartered in Philadelphia, PA.

Paranovus Entertainment Technology Ltd. engages in the research, development, manufacture, and sale of nutraceutical and dietary supplement products in the People's Republic of China and internationally. It operates through the following segments: Healthcare products, Automobile, Online Store, and Internet Information and Advertising Service. The company was founded on February 9, 2018 and is headquartered in Nanping City, China.